Purdue’s Young Institute Pharmaceutical Manufacturing Consortium is working to address bottlenecks in efficiency, contamination control, and regulatory compliance.
William Blair analyst Andy Hsieh in a note to investors said the comprehensive agreement mitigates supply chain risk for Viking’s VK2735 dual GLP-1/GIP agonist.